Tata Elxsi announced its Q4 FY26 financial results, reporting revenue of ₹993.8 crores with a quarter-on-quarter growth of 0.9% in constant currency terms. The company demonstrated strong operational performance with EBITDA margin expanding by 130 basis points to 24.6%, reflecting continued focus on operational excellence and margin improvement initiatives.

Financial Performance Overview

The company's financial metrics for Q4 FY26 showed mixed performance across business verticals:

Transportation Business Shows Resilience

The transportation vertical delivered modest growth of 0.2% quarter-on-quarter in constant currency terms, supported by strategic deal wins. The company secured two significant contracts during the quarter - one from a new-age OEM in the APAC region and another from a next-generation mobility services company in the US. These wins demonstrate the success of Tata Elxsi's strategic pivot towards OEM business, with OEM customers now representing 77% of the transportation vertical's revenue.

Management highlighted that the shift to OEM-focused business continues to strengthen their market position, with these new deals expected to contribute to growth in coming quarters through planned ramp-ups over the next 6-12 months.

Healthcare Vertical Faces Temporary Setback

The Healthcare and Life Sciences vertical experienced a decline of 13.1% quarter-on-quarter in constant currency terms, primarily due to delays in expected deal closures. Management indicated that several large deals they were confident of closing during Q4 were pushed to Q1 FY27, creating a temporary revenue impact.

Despite the quarterly decline, the company achieved a significant milestone by opening an offshore development center for Japanese MedTech leader Terumo Corporation. This center integrates design, engineering, and digital capabilities to innovate cardiac and vascular solutions, representing a strategic partnership expansion.

Media and Communication Delivers Strong Growth

The Media and Communication business posted robust growth of 5.6% quarter-on-quarter in constant currency terms, driven by continued deal ramp-ups and strategic contract wins. Key growth drivers included:

Margin Expansion Strategy

CFO Gaurav Bajaj provided detailed insights into the 130 basis points margin improvement, attributing the gains to multiple factors:

The company targets reaching 27% PBT margin by Q4 FY27 exit, focusing on gradual improvements aligned with top-line growth.

GenAI and Technology Advancement

Tata Elxsi significantly advanced its GenAI adoption during FY26 through comprehensive initiatives including partnerships with AI companies, launch of proprietary automotive SDLC platform DevStudio.ai, curated tool stacks, and rigorous employee upskilling programs. The company is progressing toward becoming an AI-native engineering organization to strengthen differentiation and innovation capabilities.

Management noted varying GenAI adoption rates across verticals, with media and telecom showing higher client interest compared to automotive and healthcare, where regulatory requirements necessitate more specialized AI solutions.

Outlook and Strategic Focus

For FY27, management revised growth expectations to high single digits from earlier double-digit aspirations, citing geopolitical uncertainties and market conditions. The company remains focused on scaling differentiated design-led and AI-enabled offerings while strengthening operational leverage to drive sustainable growth and healthy margins across all three business verticals.

Tata Elxsi has received a comprehensive downgrade from Morgan Stanley, which has revised its rating to Underweight and substantially cut the target price amid concerns over recent financial performance, segment-specific challenges, and moderated growth prospects.

Rating and Target Price Revision

Morgan Stanley has made significant adjustments to its outlook on Tata Elxsi following disappointing quarterly performance:

Performance Challenges and Segment Weakness

The company's recent quarterly results showed significant challenges across key business segments. Revenue performance missed estimates, primarily driven by weakness in both healthcare and automotive segments, which represent crucial growth drivers for the company.

Revised Growth and Earnings Outlook

Morgan Stanley has significantly moderated its projections for the company, reflecting concerns about near-term prospects amid macro volatility and delayed recovery expectations:

The brokerage has moved its growth expectations for FY27 to high single digits from the earlier projection of 10.40%, representing a significant moderation in outlook. The EPS cuts of approximately 3.70% for FY27 and 6.80% for FY28 reflect the impact of operational challenges and delayed recovery amid ongoing macro volatility. This comprehensive revision in financial projections, combined with unfavorable risk-reward dynamics, has led Morgan Stanley to adopt a cautious stance on the stock.